TY - JOUR
T1 - Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy
AU - Villain, Franck
AU - Parel, Jean Marie
AU - Kiss, Katalin
AU - Parish, Richard K.
AU - Kühne, François
AU - Takesue, Yoshiko
AU - Hostyn, Patrick
N1 - Funding Information:
We are grateful to the Florida Lions Eye Bank for support. The Senmed Corporation is sponsoring the polymer development and testing of this project. The University of Miami has proprietary interests. W. Lee and D. Denham did the mechanical engineering, and I. Nose the electrical engineering. S. Cousins, M.D. and P. Rubsamen, M.D., performed the vitreous cavity implantation assisted by E. Hernandez, L.A.T, who also performed the ERGs, fundus photography and daily animal follow-up.
Publisher Copyright:
© 1993 SPIE. All rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 1993/6/24
Y1 - 1993/6/24
N2 - Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.
AB - Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.
UR - http://www.scopus.com/inward/record.url?scp=9044237851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9044237851&partnerID=8YFLogxK
U2 - 10.1117/12.147533
DO - 10.1117/12.147533
M3 - Conference article
AN - SCOPUS:9044237851
VL - 1877
SP - 240
EP - 244
JO - Proceedings of SPIE - The International Society for Optical Engineering
JF - Proceedings of SPIE - The International Society for Optical Engineering
SN - 0277-786X
T2 - Ophthalmic Technologies III 1993
Y2 - 17 January 1993 through 22 January 1993
ER -